Coherus BioSciences (NASDAQ:CHRS) and Beam Therapeutics (NASDAQ:BEAM) Head to Head Survey
Coherus BioSciences (NASDAQ:CHRS) and Beam Therapeutics (NASDAQ:BEAM) Head to Head Survey
Coherus BioSciences (NASDAQ:CHRS – Get Rating) and Beam Therapeutics (NASDAQ:BEAM – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
科赫魯生物科學公司(納斯達克代碼：CHRS-GET Rating)和比姆治療公司(納斯達克代碼：BEAM-GET Rating)都是醫療公司，但哪隻股票更好？我們將根據這兩家公司的風險、估值、盈利能力、收益、股息、分析師推薦和機構持股等方面的實力進行比較。
Profitability
盈利能力
This table compares Coherus BioSciences and Beam Therapeutics' net margins, return on equity and return on assets.
此表比較了Coherus BioSciences和Beam Treeutics的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Coherus BioSciences | -116.54% | -422.10% | -47.03% |
| Beam Therapeutics | -343.05% | -38.93% | -21.67% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 柯赫魯斯生物科學 | -116.54% | -422.10% | -47.03% |
| BEAM治療 | -343.05% | -38.93% | -21.67% |
Earnings & Valuation
收益與估值
This table compares Coherus BioSciences and Beam Therapeutics' gross revenue, earnings per share and valuation.
此表比較了Coherus BioSciences和Beam Treeutics的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coherus BioSciences | $326.55 million | 2.15 | -$287.10 million | ($3.60) | -2.51 |
| Beam Therapeutics | $51.84 million | 60.55 | -$370.64 million | ($4.54) | -9.81 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 柯赫魯斯生物科學 | 3.2655億美元 | 2.15 | -2.871億美元 | ($3.60) | -2.51 |
| BEAM治療 | 5184萬美元 | 60.55 | -3.7064億美元 | ($4.54) | -9.81 |
Risk and Volatility
風險和波動性
Coherus BioSciences has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500.
Coherus BioSciences的貝塔係數為0.91，這意味着其股價的波動性比標準普爾500指數低9%。相比之下，Beam Treateutics的貝塔係數為1.69，這意味着其股價的波動性比標準普爾500指數高69%。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings and target prices for Coherus BioSciences and Beam Therapeutics, as reported by MarketBeat.com.
據MarketBeat.com報道，這是Coherus BioSciences和Beam Treeutics最近的評級和目標價格細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coherus BioSciences | 0 | 2 | 2 | 0 | 2.50 |
| Beam Therapeutics | 0 | 2 | 4 | 0 | 2.67 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 柯赫魯斯生物科學 | 0 | 2 | 2 | 0 | 2.50 |
| BEAM治療 | 0 | 2 | 4 | 0 | 2.67 |
Coherus BioSciences presently has a consensus target price of $16.50, indicating a potential upside of 82.93%. Beam Therapeutics has a consensus target price of $74.86, indicating a potential upside of 68.07%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than Beam Therapeutics.
Coherus BioSciences目前的共識目標價為16.50美元，潛在漲幅為82.93%。BEAM治療公司的共識目標價為74.86美元，表明潛在上行空間為68.07%。考慮到Coherus生物科學公司更有可能的上行空間，分析師們顯然認為Coherus生物科學公司比BEAM治療公司更有利。
Insider & Institutional Ownership
內部人與機構所有權
99.5% of Coherus BioSciences shares are owned by institutional investors. Comparatively, 76.7% of Beam Therapeutics shares are owned by institutional investors. 11.9% of Coherus BioSciences shares are owned by company insiders. Comparatively, 4.0% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Coherus BioSciences 99.5%的股份由機構投資者持有。相比之下，比姆治療公司76.7%的股份由機構投資者持有。Coherus BioSciences 11.9%的股份由公司內部人士持有。相比之下，比姆治療公司4.0%的股份由公司內部人士持有。強大的機構持股表明，對衝基金、捐贈基金和大型基金經理相信，從長期來看，一隻股票的表現將好於大盤。
Summary
摘要
Coherus BioSciences beats Beam Therapeutics on 8 of the 14 factors compared between the two stocks.
在兩隻股票之間的14個因素中，Coherus BioSciences在8個因素上擊敗了Beam Treateutics。
About Coherus BioSciences
科赫魯斯生物科學公司簡介
(Get Rating)
(獲取評級)
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Coherus BioSciences，Inc.是一家生物製藥公司，主要在美國專注於生物相似和免疫腫瘤學市場。該公司銷售UDENYCA，一種生物類似於Neulasta的藥物，Neulasta是美國的一種長效粒細胞刺激集落因子。其流水線產品包括Humira、阿瓦斯丁和Lucentis的生物仿製藥。該公司還開發了用於中國黑色素瘤二線治療的新型抗PD-1抗體Toripalimab、貝伐單抗生物類似物和抗腫瘤壞死因子候選產品CHS-1420，作為adalimumab生物類似物、ranibizumab生物類似物。Coherus BioSciences，Inc.與Selexis SA、AbbVie，Inc.、輝瑞公司、Bioeq AG、InnoventBiologics(蘇州)有限公司和君士生物科學公司簽署了許可協議。該公司前身為Biogenerics，Inc.，並於2012年4月更名為Coherus BioSciences，Inc.。Coherus BioSciences，Inc.成立於2010年，總部位於加利福尼亞州雷德伍德市。
About Beam Therapeutics
關於BEAM治療
(Get Rating)
(獲取評級)
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
BEAM治療公司是一家生物技術公司，在美國為患有嚴重疾病的患者開發精密基因藥物。該公司正在開發用於治療鐮狀細胞疾病和貝塔地中海貧血的BEAM-101；用於治療鐮狀細胞疾病的BEAM-102；以及用於治療復發/難治性T細胞急性淋巴細胞白血病的同種異基因嵌合抗原受體T細胞BEAM-201；以及用於治療Ia型糖原儲存疾病患者的肝臟靶向開發候選藥物BEAM-301。它還開發治療阿爾法-1抗胰蛋白酶缺乏症、眼部疾病以及其他肝臟、肌肉和中樞神經系統疾病的藥物。該公司與波士頓兒童醫院結成聯盟；與Magenta治療公司達成研究和臨牀試驗合作協議；與Sana生物技術公司達成許可協議；與巴塞爾分子和臨牀眼科研究所達成研究合作。它還與輝瑞公司和Apellis製藥公司簽訂了研究合作協議；以及與Verve治療公司的合作和許可協議。該公司成立於2017年，總部設在馬薩諸塞州劍橋市。
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Coherus生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Coherus BioSciences和相關公司的最新新聞和分析師評級的每日簡要摘要。